Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimatoprost Ocular Insert in Glaucoma and Ocular Hypertension
NCT02358369Phase 2Completed
- Sponsor
- ForSight VISION5
- Start
- Jan 2015
- Primary completion
- Aug 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by ForSight VISION5. Primary endpoints: Change From Baseline in Intraocular Pressure (IOP) at 12 weeks, Percentage of Participants by Change From Baseline in Best-corrected Visual Acuity (BCVA) Categories at 12 weeks and 4 more. Started Jan 2015; status: completed.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02358369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358369.